Maxygen and Aventis Pasteur Enter Strategic Alliance to Develop Improved Vaccines

06-Nov-2001
Maxygen, Inc. (Nasdaq:MAXY) and Aventis Pasteur today announced the signing of a three-year agreement to develop improved vaccines for a specific undisclosed target. Maxygen’s MolecularBreedingâ„¢ directed molecular evolution technologies are ideally suited to improve vaccine products in key ways, including improving immunogenicity, purity and manufacturability. Under the terms of the agreement, Maxygen will receive license fees, full research and development funding, minimum annual royalties, and potential milestone and royalty payments on product sales. Aventis Pasteur will receive exclusive worldwide rights to commercialize the vaccines developed in the collaboration. “The collaboration with Aventis Pasteur is an important milestone in our strategic focus to develop vaccines and protein pharmaceuticals to treat serious unmet medical needs. This is the third significant pharmaceutical partnership that we have signed this year,â€

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!